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Edited by Robert BaroukiAbstract Legumain/asparaginyl endopeptidase (EC 3.4.22.34)
is a novel cysteine protease that is abundantly expressed in the
late endosomes and lysosomes of renal proximal tubular cells.
Recently, emerging evidence has indicated that legumain might
play an important role in control of extracellular matrix turnover
in various pathological conditions such as tumor growth/metasta-
sis and progression of atherosclerosis. We initially found that
puriﬁed legumain can directly degrade ﬁbronectin, one of the
main components of the extracellular matrix, in vitro. Therefore,
we examined the eﬀect of legumain on ﬁbronectin degradation in
cultured mouse renal proximal tubular cells. Fibronectin process-
ing can be inhibited by chloroquine, an inhibitor of lysosomal
degradation, and can be enhanced by the overexpression of legu-
main, indicating that ﬁbronectin degradation occurs in the pres-
ence of legumain in lysosomes from renal proximal tubular cells.
Furthermore, in legumain-deﬁcient mice, unilateral ureteral
obstruction (UUO)-induced renal interstitial protein accumula-
tion of ﬁbronectin and renal interstitial ﬁbrosis were markedly
enhanced. These ﬁndings indicate that legumain might have an
important role in extracellular matrix remodeling via the degra-
dation of ﬁbronectin in renal proximal tubular cells.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Legumain/asparaginyl endopeptidase (EC 3.4.22.34) is a cys-
teine peptidase that hydrolyzes asparaginyl bonds [1], and it is*Corresponding author. Fax: +81 77 543 3858.
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doi:10.1016/j.febslet.2007.02.064known to be an ortholog of plant vacuolar processing enzyme
(VPE) [2]. VPEs are involved in maturation and/or activation
of various vacuolar proteins in plants [3,4], and VPE has been
shown to be a protease essential for a virus-induced hypersen-
sitive response that involves programmed cell death of plants
[5]. Mammalian legumain, a homologue of VPE, was ﬁrst iso-
lated from the pig kidney [6], and the enzyme has been shown
to play a regulatory role in the biosynthesis of lysosomal en-
zymes [7].
Legumain is known to exist in a number of mammalian tis-
sues, such as the kidney, placenta, spleen, liver, and testis [8].
Among these organs, the speciﬁc activity of legumain is higher
in the kidney. We previously reported that legumain is mainly
expressed in proximal tubules of the rat kidney [9]. In legu-
main-deﬁcient mice, it has been found that lysosomes of renal
proximal tubular cells are enlarged and the processing of lyso-
somal peptidases in the kidneys is completely defective [7].
These ﬁndings indicate that legumain might have an important
role in lysosome functions of renal proximal tubuler cells.
However, the physiological or pathological roles of legumain
in the kidney have not been elucidated.
Recently, emerging evidence has been indicated that legu-
main might play an important role in tumor growth/metastasis
and carotid artery-atherosclerosis development [10–15], sug-
gesting that legumain controls extracellular matrix turnover
in various pathological conditions. Therefore, we examined
whether legumain can control extracellular matrix turnover
in the kidney, particularly in renal proximal tubular cells.
We found that legumain degrades ﬁbronectin, the main com-
ponent of extracellular matrix protein [16–21], in cultured re-
nal proximal tubular cells. Furthermore, in legumain-
deﬁcient mice, the protein accumulation of ﬁbronectin in the
tubulointerstitial area was markedly enhanced in the model
of renal interstitial ﬁbrosis, unilateral ureteral obstruction
(UUO) [22–25]. The results of the present study indicate
that legumain can regulate extracellular matrix turnover
through the degradation of ﬁbronectin in renal proximal
tubular cells.blished by Elsevier B.V. All rights reserved.
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2.1. Reagents
Reagents were purchased from the following vendors: ﬂuorogenic
peptide substrate, Z-Ala-Ala-Asn-MCA, from Peptide Institute (Osa-
ka, Japan); pCMV/myc vector, enhanced chemiluminescence (ECL)
kit, anti-rabbit IgG horseradish peroxidase-linked whole antibody,
and anti-mouse IgG horseradish peroxidase-linked whole antibody
from Amersham Pharmacia Biotech (Piscataway, NJ, USA); rabbit
polyclonal anti-ﬁbronectin antibody for Western blot from Biogene-
sis (Poole, UK), mouse monoclonal anti-ﬁbronectin antibody for
immunohistochemistry from Sigma Chemical (St. Louis, MO, USA);
mouse monoclonal anti-glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) from Chemicon (Temecula, CA, USA); Lipofectamin
2000 reagent from Invitrogen (Carlsbad, CA, USA); reverse transcript
reagents from TAKARA BIO (Otsu, Japan), iQSYBR Green Super-
mix from Bio-Rad Laboratories (Hercules, CA, USA); Chloroquine
from Sigma Chemicals (Temecula, CA, USA); Quick Start Bradford
Protein Assay Kit and polyvinylidene diﬂuoride (PVDF) membranes
from BioRad; Rapid plasmid MAXI Prep system from Marligen
(Ijamsville, MD, USA); Ligation High and DH5a Competent High
from TOYOBO (Osaka, Japan); EZ-Link Sulfo-NHS-LC-Biotin
from PIERCE (Rockford, IL, USA); TRIzol Reagent from GIBCO
BRL (Grand Island, NY, USA); Streptavidin conjugated with horse-
radish peroxidase from ZYMED (San Francisco, CA, USA); and His-
toﬁne SAB-PO kit from Nichirei (Tokyo, Japan). Rabbit anti-mouse
legumain antibody was prepared as previously described [7]. Human
ﬁbronectin, bovine kidney legumain, and human cystatin C were puri-
ﬁed as previously reported [9,26,27]. Mouse renal proximal cells (deriv-
ative, patent WO9927363, Japan, USA, and EU) were kindly provided
by CMIC Co. Ltd. (Japan).
2.2. Western blot analysis
Protein from kidney tissues was extracted with lysis buﬀer (1% Non-
idet P-40, 0.1% SDS, 1 mM PMSF, 0.5% sodium deoxycholate and
1 mM sodium orthovanadate, and 1 mM sodium ﬂuoride in PBS).
After determination of protein concentrations, 20 lg of the protein
was mixed with an equal amount of 2· SDS loading buﬀer (100 mM
Tris–HCl, 4% SDS, 20% glycerol and 0.2% bromophenol blue) for
Western blot analysis as described previously [28].
2.3. Degradation of ﬁbronectin
Puriﬁed human ﬁbronectin (20 pmol) was incubated with 2 pmol of
puriﬁed bovine legumain in 50 mM sodium citrate buﬀer, pH 5.0, and
5 mM b-mercaptoethanol (ME) with or without human cystatin C
(10 pmol) for the indicated times. The samples were subjected to
SDS–PAGE, and the gels were stained with Coomassie Brilliant blue
R-250, or those were for immunoblot analysis probed with anti-ﬁbro-
nectin monoclonal antibody or anti-legumain antibody as previously
described [3,27]. The ﬁbronectin digested with legumain after separa-
tion in SDS–PAGE was blotted onto PVDF membranes for determi-
nation of the amino acid sequence of the N-terminal region of
digested ﬁbronectin. Proteins on the membranes were stained with
Coomassie blue, and each fragment transferred to the membrane
was cut and sequenced using an Applied Biosystems Model 492 CL
Protein Sequencer.
2.4. Cell culture
Mouse renal proximal tubular cells were cultured as previously de-
scribed [29,30]. Sub-conﬂuent cells were made quiescent by incubation
with 0.2% fatty acid-free bovine serum albumin (BSA)-Dulbecco’s
modiﬁed Eagle’s medium (DMEM) for 24 h prior to the experiments.2.5. Fibronectin degradation in cultured mouse renal proximal cells
Puriﬁed human ﬁbronectin were biotinylated using EZ-Link Sulfo-
NHS-LC-Biotin according to the manufacturer’s protocol. The biotin-
ylated ﬁbronectin (20 pmol) was added to the culture medium and
incubated with or without 50 mM chloroquine for the indicated times.
The cells were lysed in SDS sample buﬀer buﬀer (20 mM Tris phos-
phate, pH 7.0, 0.2% SDS, 1 M urea, 10% glycerol, 5 mM b-ME and
0.01% bromphenol blue). Thirty microliters of culture medium was
electrophoresed on 10% SDS–PAGE gels and transferred to PVDF
membranes. After the membranes had been blocked, they were incu-bated with a 1:1000 dilution of streptavidin conjugated with horserad-
ish peroxidase at 4 C for 30 min. The reactive bands were detected
with an ECL system.
2.6. DNA constructions and transient transfection
Full-length mouse legumain cDNA was ampliﬁed by polymerase
chain reaction (PCR) using original primer leg F ([5-CGGAATTCC-
GAGAATGACCTGGAGAGTGG-3]) and leg R([5-CCGCTCGA-
GCGGCTCACTCATTGGGAAGCG-3]), including the EcoRI and
XhoI digestion site, respectively, as a template, using cDNA from
mouse renal proximal tubular cells. The ampliﬁed PCR product was
subcloned into pCMV myc vector at EcoRI/XhoI (pCMV-Leg). Mouse
proximal tubular cells (1 · 106) were transfected with 3 lg of pCMV-
Leg using Lipofectamine 2000 for 24 h according to the instructions
of the manufacturer. Fibronectin degradation was determined as de-
scribed above.
2.7. Assay of legumain activity
The cells were lysed in legumain assay buﬀer (50 mM sodium citrate,
pH 5.0, 5 mM b-ME 0.8% Nonidet P-40). The cell lysates were centri-
fuged at 15000 · g for 20 min, and supernatants were collected to as-
say the enzyme activities or protein contents. The enzyme activity of
legumain was measured by ﬂuorometrical determination (excitation,
380 nm; emission, 440 nm) of the liberation of AMC at 37 C in a mix-
ture containing 10 mL of 10 mM substrate Z-Ala-Ala-Asn-MCA,
which is a speciﬁc substrate for legumain, 100 mL of 0.5 M sodium cit-
rate buﬀer (pH 5.0), 50 mL of cell lysate, and Milli Q water (18 m) in a
total volume of 1 mL. After incubation for 2 h, 2 mL of 0.2 M acetic
acid was added to the mixture to terminate the reaction. Protein assay
was performed by the Bradford method. One unit of activity was de-
ﬁned as the amount of enzyme that hydrolyzed 1 mmol of the substrate
per min [9].
2.8. Animals
Studies were performed on 14-week-old male C57BL/6J wild-type
(n = 12) and legumain-deﬁcient mice (n = 12). Legumain-deﬁcient mice
have a genetic background of C57BL/6J. Legumain-deﬁcient mice were
prepared as previously described [7]. All experimental procedures were
performed according to the regulations of the Research Center for
Animal Life Science of Shiga University of Medical Science.
2.9. Experimental design of unilateral ureteral obstruction (UUO)
UUO was performed as described previously [22]. In brief, under
intraperitoneal pentobarbital anesthesia, the left kidney and ureter
were exposed via a ﬂank incision. The left ureter was ligated with 4-
0 silk at two points and cut between the ligatures in order to prevent
retrograde urinary tract infection. Finally, the wound was close in
layers. At 10 days after surgery, the animals were killed, and both
obstructed and contralateral kidneys were removed. The kidneys were
immersed into 10% neutral-buﬀered formalin for histopathological and
immunohistochemical examinations.
2.10. Quantitative real-time PCR
Total RNA (1 lg) was extracted from tissue by using TRIzol reagent
(Life Technologies, Grand Island, NY) according to the manufac-
turer’s protocol. Total RNA was reverse-transcripted using reverse
transcript reagents. Real-time PCR was performed using speciﬁc
mouse ﬁbronectin ([5-AGA CCA TAC CTG CCG AAT GTA G-3]
and [5-GAG AGC TTC CTG TCC TGT AGA G-3]) and GAPDH
([5-TGA ACG GGA AGC TCA CTG G-3] and [5-TCC ACC ACC
CTG TTG CTG TA-3]) primers in a real-time quantitative PCR sys-
tem (ABI Prism TM 7500 Sequence Detection System, Perkin–Elmer
Applied Biosystems). Each reaction mixture contained 5 ll of sample
DNA, 4 lL of iQSYBR Green Supermix and 0.5 mM of each primer.
mRNA levels were quantiﬁed using standard curve method. Standard
curves were constructed using serially diluted standard template. Ct
value was used to compute mRNA levels from the standard curve.
Analytical data were adjusted with internal control glyceraldehyde-
3-phosphate dehydrogenase (GAPDH).2.11. Histopathological examination
Fixed tissues in 10% neutral-buﬀered formalin were dehydrated in
graded alcohol and embedded in paraﬃn. Paraﬃn sections (3 lm
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ium, which were stained blue with Azan staining, were identiﬁed on
digital images using a computer-aided manipulator (MetaMorph, Uni-
versal Imaging, Downingtown, PA). The paraﬃn sections (3 lm thick)
were also used for immunohistochemical studies of ﬁbronectin, with a
monoclonal mouse antibody to ﬁbronectin. Immunostaining was per-
formed by the streptavidin–biotin immunoperoxidase method using a
histoﬁne SAB-PO kit according to the instructions of the manufac-
turer. To evaluate the immunostaining of ﬁbronectin, 20 randomly
chosen tubulointerstitial areas per mouse were graded semiquantita-
tively in a double-blind manner by two independent observers. The to-
tal of ﬁbrotic areas stained with Azan and the degrees of ﬁbronectin
expression were graded as follows: 0, normal pattern; 0.5, very rare,
trace interstitial foci; 1, <5% of the cortex exhibiting locally increased
staining; 2, 5–10%; 3, 10–20%; 4, 20–30%; and 5, >30% of the cortex
exhibiting positive staining [31].
2.12. Statistical analysis
Values are means ± standard errors (S.E.). Analysis of variance fol-
lowed by the t test was used to determine signiﬁcance of diﬀerences in
multiple comparisons. P < 0.05 was deﬁned as statistically signiﬁcant.3. Results
3.1. Legumain directly degrades ﬁbronectin in vitro
To determine the eﬀects of legumain on turnover of extracel-
lular matrix proteins, we ﬁrst examined whether puriﬁed bo-
vine legumain can degrade puriﬁed ﬁbronectin, one of the
main components of the extracellular matrix, in vitro. When
legumain and ﬁbronectin were co-incubated, a 230-kDa band
appeared at 10 min, a 80-kDa band appeared at 30 min, and
multiple bands appeared at 3 h (Fig. 1), indicating that legu-
main can directly degrade ﬁbronectin in vitro. We examined
the eﬀect of cystatin C, which is a natural cystein peptidase
inhibitor and can inhibit the activity of legumain [6,32], onA
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Fig. 1. Degradation of human ﬁbronectin by bovine legumain (A, B, and C)
(A, B, and C) Human ﬁbronectin (20 pmols) was incubated with or without
The reactants were subjected to SDS–PAGE (A) and immunoblot analyses
Lanes: 1, bovine legumain without human ﬁbronectin; 2, human ﬁbronectin w
legumain for 10 min (3), 30 min (4), 1 h (5), 3 h (6), and 12 h (7); and 8, puriﬁ
10 min, to which human ﬁbronectin (20 pmols) was added and incubated at
puriﬁed bovine legumain (2 pmols) at 37 C for 12 h. The reactants were sub
The N-terminal amino acid sequences of the fragments of ﬁbronectin were dthe ﬁbronectin degradation attained with legumain. Pre-incu-
bation of puriﬁed human cystatin C inhibited the ﬁbronectin
degradation attained with legumain (Fig. 1, lane 8). Further-
more, we analyzed N-terminal amino acid sequences of the
fragments of ﬁbronectin degraded by legumain. The four frag-
ments (numbered 2, 4, 5, and 6 in Fig. 1 D) showed identical
sequences for the region of alanine601-proline602-gluta-
mine603-proline604-serine605-histidine606 residues in the human
ﬁbronectin molecule, indicating that legumain cleaves human
ﬁbronectin between asparagine600 and alanine601 [33].3.2. Legumain degrades ﬁbronectin in cultured mouse renal
proximal tubular cells
We examined the roles of legumain in the degradation of
ﬁbronectin in cultured mouse renal proximal tubular cells by
incubating these cells with biotinylated human ﬁbronectin.
Since legumain has been reported to be a lysosomal enzyme
[7,9], we inhibited the function of lysosomes with chloroquine,
which increases the pH of the lysosomes [33]. Indeed, chloro-
quine inhibited the activity of legumain inmouse proximal tubu-
lar cells by 10-h treatment: about 20% activities compared to
that without chloroquine (Fig. 2A). The amount of biotinylated
ﬁbronectin in the culturemediumwasmarkedly increased by co-
incubation with chloroquine (Fig. 2B). These ﬁndings indicate
that the lysosomal activity is necessary for the degradation of
ﬁbronectin in cultured renal proximal tubular cells. We also
examined the eﬀect of legumain over-expression on degradation
of ﬁbronectin in renal proximal tubular cells. The amount of
biotinylated ﬁbronectin was markedly decreased in the culture
medium of legumain-overexpressing cells (Fig. 2C). These re-
sults suggest that legumain regulates the degradation of ﬁbro-
nectin in cultured mouse renal proximal tubular cells.1
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Fig. 2. Legumain can control ﬁbronection degradation in cultured
mouse renal proximal tubular cells. (A) Mouse proximal tubular cells
were incubated with or without chloroquine for 10 h, and the activity
of legumain was assayed. Data are means ± S.E. n = 3. **, P < 0.01,
signiﬁcantly diﬀerent vs. control. (B) Mouse proximal tubular cells
were incubated with the biotinylated ﬁbronectin (20 pmol) for 24 h
without (lanes 1 and 2) or with a 10-h incubation of chloroquine
(50 mM, lanes 3 and 4). The culture medium (30 lL) was subjected to
SDS–PAGE and was then transferred onto PVDF membranes. The
membranes were incubated with horseradish peroxidase-conjugated
streptavidin. (C) The cells were transfected with pCMV-legumain
plasmid or an empty control vector and then incubated with
biotinylated ﬁbronectin (20 pmol) for 24 h. Degradation of the labeled
ﬁbronectin was assayed as described above. Lanes 1 and 2, from the
cells transfected with the empty vector; lanes 3 and 4, from the cells
transfected with the legumain-overexpression plasmid. The arrow in
each panel indicates the biotinylated puriﬁed ﬁbronectin. The results
shown in each panel are representative of three independent experi-
ments.
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Fig. 3. The mRNA expression of ﬁbronectin assayed by real-time
PCR shows no signiﬁcant diﬀerence in wild-type mice and legumain-
deﬁcient mice. Real-time PCR showed that a marked increase in
ﬁbronectin mRNA expression level was evident in obstructive kidneys
in both wild-type mice (WT) and legumain-deﬁcient mice (Leg/)
mice at day 10 after UUO. However, there was no signiﬁcant diﬀerence
between the expression levels of ﬁbronectin mRNA in UUO kidneys of
legumain-deﬁcient mice and wild-type mice. Each bar represents the
mean ± S.E.M. for at least ﬁve mice. *, P < 0.001. n.s., the diﬀerences
between the activities of these enzymes in wild-type and legumain-
deﬁcient mice were not statistically signiﬁcant (P > 0.05).
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interstitial ﬁbrosis is signiﬁcantly enhanced in legumain-
deﬁcient mice
To further evaluate the role of legumain in the degradation
of ﬁbronectin in the kidney in vivo, we next examined the renal
ﬁbrosis model in legumain-deﬁcient mice. In the UUO kidneys,
mRNA expression of ﬁbronectin was signiﬁcantly enhanced in
both wild-type mice and legumain-deﬁcient mice, but no signif-
icant diﬀerence was found mRNA expression levels of ﬁbro-
nection between wild-type mice and legumain-deﬁcient mice
(Fig. 3). However, the protein accumulation of ﬁbronectin in
the obstructed kidneys was signiﬁcantly enhanced in legu-
main-deﬁcient mice compared with that in wild-type mice
(Fig. 4). Furthermore, renal interstitial ﬁbrosis evaluated with
Azan staining was signiﬁcantly extensive in the UUO kidneys
from legumain-deﬁcient mice (Fig. 5).4. Discussion
In the present study, we demonstrated that legumain, a no-
vel lysosomal peptidase, can regulate the degradation of ﬁbro-
nection in mouse renal proximal tubular cells. First, we
showed that puriﬁed bovine legumain can digest human ﬁbro-
nectin in a test tube and initially cleaves it at asparagine600-ala-
nine601; however, these reactions are inhibited by the cysteine
protease inhibitor cystatin C. Since legumain is a cysteine pep-
tidase that hydrolyzes asparaginyl bonds, the above results
suggest that legumain can directly degrade ﬁbronectin
in vitro. Second, we showed that the ﬁbronectin processing
in cultured mouse renal proximal tubular cells is inhibited by
an inhibitor of lysosomal degradation, chloroquine, and its
degradation is, on the contrary, enhanced by the overexpres-
sion of legumain. No enzyme activities or immuno-reactivities
of legumain could be detected in our culture medium from
mouse renal proximal tubular cells (data not shown). Legu-
main requires an acidic environment for optimal catalytic
activity [1,6–8,34]; thus, it might be inactive in culture medium.
Furthermore, turnover of matrix ﬁbronectin has been shown
to involve caveolin-1-mediated endocytosis and intracellular
lysosomal degradation in embryonic myoﬁbroblast cells [35].
Therefore, our data indicate that ﬁbronectin may be taken
up and degraded intracellularly by legumain in renal proximal
tubular cells. Finally, the accumulation of ﬁbronectin in the re-
nal tubulointerstitial area was signiﬁcantly enhanced in UUO
kidneys from legumain-deﬁcient mice. However, there was
no signiﬁcant diﬀerence in the expression of ﬁbronectin
mRNA in the kidneys between legumain-deﬁcient mice and
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function loss. Early in the induction of progressive renal dis-
ease, events occur within tubulointerstitial cells that are critical
to the subsequent accumulation of extracellular matrix pro-
teins in the interstitial space [38,39]. Excessive matrix accumu-
lation of matrix proteins is thought to be the consequence of
two parallel processes: increased synthesis and decreased deg-
radation. Fibronectin is one of the main components of the
extracellular matrix [16,21], and ﬁbronectin polymerization
into the extracellular matrix is required for the deposition of
collagen-I and thrombospondin-1 as well as maintenance of
the extracellular matrix; thus, it is thought to be a key regula-
tor of extracellular matrix composition and stability [19].
Therefore, marked renal ﬁbrosis in the UUO kidneys from
legumain-deﬁcient mice might be caused through the impaired
ﬁbronectin degradation by legumain in renal proximal tubular
cells.
Renal tubulointerstitial cells also synthesize several pepti-
dases, such as metalloproteinases (MMP-2 and MMP-9), ser-
ine proteases (urokinase-type plasminogen activator) and
lysosomal cathepsins, that can degrade extracellular matrixproteins [40]. These peptidases are thought to be secreted
and activated and to function mainly in the extracellular envi-
ronment. Furthermore, legumain is a potential activator of
matrix metalloproteinases and cathepsins [7,41]; thus, there is
also the possibility that legumain controls the remodeling of
other components of extracellular matrices through the pro-
cessing of other lysosomal peptidases.
Legumain is abundantly expressed in the kidney and local-
ized in the late endosomes and lysosomes of proximal tubular
cells [7,34]. We previously reported that legumain cleaves vita-
min D-binding protein, which is endocytosed into proximal
tubular cells via megalin [9]. In the present study, we have
shown that legumain can also regulate the degradation of
ﬁbronectin in renal proximal tubular cells in both in vitro
and in vivo conditions. Our data also indicate that legumain
plays important roles in the functions of renal proximal tubu-
lar cells, such as the absorption of macromolecules and the
remodeling of extracellular matrix proteins. The extracellular
matrix remodeling of these cells is thought to contribute to
the pathogenesis of renal interstitial ﬁbrosis. Our ﬁndings
may be useful for elucidation of the precise mechanisms of
Y. Morita et al. / FEBS Letters 581 (2007) 1417–1424 1423renal interstitial ﬁbrosis, and they also evoke a novel therapeu-
tic concept for this pathological condition, implying that
pharmacological modulation of legumain activity may control
the progression of renal ﬁbrosis.
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